Navigation Links
Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
Date:12/15/2010

SAN DIEGO, Dec. 15, 2010 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that it has successfully identified a novel pre-clinical candidate for its newest lysophosphatidic acid (LPA)-related program, autotaxin.  Autotaxin is an enzyme upstream from LPA receptors and has been implicated in a number of diseases including rheumatoid arthritis, glioblastoma, lung, breast, ovarian and thyroid cancers.

"We are pleased to announce that we have identified an orally bioavailable and highly selective autotaxin inhibitor," said Peppi Prasit, Ph.D., Chief Scientific Officer.  "Previous published data implicates autotaxin as a potent stimulator of tumor cell motility.  Cells over expressing autotaxin result in amplified tumorigenesis and metastatic potential.  These observations when combined with our recent pre-clinical experiments, which demonstrated that an autotaxin-specific inhibitor can successfully inhibit tumor metastases, are quite exciting."

Bob Baltera, Chief Executive Officer added, "As we have stated before, we are committed to exploring the science and medicine related to the LPA pathway.  We believe there are numerous potential drug targets in this pathway, and our autotaxin inhibitor is the latest in our portfolio of LPA-related drug targets, which also includes our LPA1 receptor antagonist AM152 which is currently in phase 1 clinical trials.  While a great deal of work remains in advancing the autotaxin program to the clinic, we look forward to communicating our progress in 2011."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and development of new drugs to treat inflammatory disease.  Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
2. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
3. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
4. Visage Imaging Releases Amira 5.3
5. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
6. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
7. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
8. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
9. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
10. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
11. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... its common stock consisting of 1,475,506 shares to be ... by certain of its stockholders. In addition, Nevro expects ... up to an additional 590,202 shares of common stock ...
(Date:6/1/2015)... , June 1, 2015 NEOVIA ONCOLOGY ... engaged in the development and commercialization of novel, ... it has met with the U.S. Food and ... filing of an Investigational New Drug (IND) application ... a result of the meeting, Neovia has clarified ...
(Date:6/1/2015)... Novel t reatments   entering the squamous ... GBI Research . The ... primarily by the introduction of numerous premium therapies, particularly in ... combine with generic chemotherapies. Analysis from business intelligence ... to 2020 - forecasts the value of the NSCLC ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3Neovia Oncology Announces First IND Meeting 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3
... Pharmasset, Inc.,(Nasdaq: VRUS ), a clinical stage pharmaceutical ... viral,infections, reported financial results for the fiscal year ended September ... cash and cash,equivalents and short term investments. , ... Clevudine , ...
... PHILADELPHIA, December 11, Rosetta Genomics, Ltd. (NASDQ: ROSG), ... the,commercial availability of its first diagnostic test, miRview(TM) ... Genomics,CLIA-certified lab in Philadelphia. , ... may contact 1-888-522-7971, or visit the,company,s website ...
Cached Medicine Technology:Pharmasset Reports Fiscal Year End 2008 Financial Results 2Pharmasset Reports Fiscal Year End 2008 Financial Results 3Pharmasset Reports Fiscal Year End 2008 Financial Results 4Pharmasset Reports Fiscal Year End 2008 Financial Results 5Pharmasset Reports Fiscal Year End 2008 Financial Results 6Pharmasset Reports Fiscal Year End 2008 Financial Results 7Pharmasset Reports Fiscal Year End 2008 Financial Results 8Pharmasset Reports Fiscal Year End 2008 Financial Results 9Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 2Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 3Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 4Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 5
(Date:6/1/2015)... June 01, 2015 KC and Monica ... $88,000 of the best superfood products in ... floods in Texas. , "Monica and I are ... News in distributing Living Fuel Super Meals - SuperBerry®, ... millennial floods in Texas," KC Craichy said. "We have ...
(Date:6/1/2015)... Atlanta, GA (PRWEB) June 01, 2015 ... leading publisher of clinical journals in the areas of ... pleased to announce that it has expanded upon its ... newest journal, Hospital Medicine Practice, in a mobile ... smartphones and tablets. , “We are very excited ...
(Date:6/1/2015)... The session, entitled “Building the Blueprint for Tomorrow’s Vehicle ... Automotive Americas, senior representatives from Ford and Delphi, ... by Andy Gryc of CX3 Marketing. The discussion will ... software in connected vehicles and autonomous cars, and will ... ecosystem can fit into new vehicle software. , ...
(Date:6/1/2015)... Strategic Radiology (SR) announced today that Rome Radiology Group ... SR coalition of progressive, independent radiology groups geographically dispersed ... have access to collective resources in all aspects of ... of subspecialized radiology services. With the addition of RRG, ... based radiology group practices. , “We are all ...
(Date:6/1/2015)... PA (PRWEB) June 01, 2015 It ... and sanitary in order to protect both care providers ... that there needs to be a way to put ... Line is a line of home-healthcare products that promotes ... care providers and patients safe from germs and disease. ...
Breaking Medicine News(10 mins):Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 2Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 3Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 2Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 3Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 2Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 3Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 4
... came into being in the seventies, evolved into an essential component ... increase with mounting pressure on pharma and biotech companies to lower ... projected to exceed $26.2 billion by the year 2012. , ... ...
... that allows more efficient use of larger cleanrooms. , ... ... designer, fabricator and installer of cleanrooms and cleanroom equipment ... into the AireCell line of extrusions. The new extrusion allows ...
... SuperFood with Super Antioxidant provides ... environmental stress, ORLANDO, Fla., Oct. 21 ... (Chennai, India) are jointly introducing a,new organic ... complex,of organic spirulina and astaxanthin in a ...
... 21, 2008) Gastroesophageal reflux disease (GERD) is ... in GI and primary care clinics, however physicians ... trials of medications and their own observations and ... Gastroenterological Association (AGA) Institute has published evidence-based guidelines ...
... of $25 Tickets Available for Purchase at the Pine Avenue ... Entrance to the Long Beach Convention Center, LOS ANGELES, ... The Village event tonight from 5:00 p.m. to 9:00 p.m.,at the ... Night at The Village will,transform the Long Beach Convention Center,s exhibit ...
... Promotes Positive Options, Educates about Dangers of Alcohol, ... 24 school districts have been named by the ... 2008 Alcohol Awareness Poster,Contest., The awards recognize ... message that underage drinking is dangerous. The,PLCB,s annual ...
Cached Medicine News:Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 2Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 3Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 4Health News:Gerbig Engineering Introduces 7 " Deep Extrusions for Cleanroom Construction 2Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 2Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 3Health News:AGA releases evidence-based GERD guidelines 2Health News:AGA releases evidence-based GERD guidelines 3Health News:Maria Shriver to Debut 'Night at The Village' Event with Rachael Ray, Billie Jean King, Dr. Mehmet Oz and Rocco DiSpirito 2Health News:Maria Shriver to Debut 'Night at The Village' Event with Rachael Ray, Billie Jean King, Dr. Mehmet Oz and Rocco DiSpirito 3Health News:PLCB Honors Winners of 2008 Alcohol Awareness Poster Contest 2Health News:PLCB Honors Winners of 2008 Alcohol Awareness Poster Contest 3Health News:PLCB Honors Winners of 2008 Alcohol Awareness Poster Contest 4
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.2 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 3.0 mm angled double bevel. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 2.85 mm slit. Blade tip dimension: 14.1 mm x 2.85 mm x 3.3 mm....
Full Handle Laseredge Slit Blade Knife, 2.8 mm angled double bevel. Blade tip dimension: N/A x 2.8 mm x N/A....
Medicine Products: